The use of IgA-antiendomysial antibody test for screening coeliac disease in insulin-dependent diabetes mellitus

被引:0
|
作者
Nosari, I
Casati, A
Mora, C
Astulfoni, A
Cortinovis, F
Maglio, ML
Lepore, G
机构
[1] OSPED RIUNITI BERGAMO,DIV ENDOCRINOL,DIABET UNIT,I-24100 BERGAMO,ITALY
[2] OSPED RIUNITI BERGAMO,DIV PAEDIAT,I-24100 BERGAMO,ITALY
关键词
antiendomysial antibody; coeliac disease; insulin-dependent diabetes mellitus;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The co-existence of coeliac disease (CD) and insulin-dependent diabetes mellitus (IDDM) was investigated using a specific recently described test: the IgA-antiendomysial antibody (EmA). All 138 ID diabetics living in the province of Bergamo and ranging 0-20 yr (mean 13.1; 54 females, 84 males; mean duration of IDDM 5.7 yr, range 1-18), whose data had been carefully derived from multiple sources, were screened over a period of six months, IgA-EmA, antigliadin IgA and IgG (AGA) and HbA(1C) were measured, Control serum samples for the same determinations were obtained from 91 subjects without intestinal problems, Student's t test and Chi-square analysis were applied, Four diabetic patients had been previously diagnosed as having biopsy proven CD, They were IgG-AGA and EmA positive at the onset of CD, Two clinically silent diabetic patients were both AGA and EmA positive; they underwent intestinal biopsy and villous atrophy was found, Twenty-two CD symptom-free EmA negative diabetics (16.6%) were IgG-AGA positive vs 5 cases of control group (5.5%) (p<0.05). The prevalence of CD in our patients (4.35%) was similar to that found in IDDs of other countries and higher than in the general population; so we suggest that IDD patients be screened routinely for CD, IgA-EmA was confirmed to be a reliable serological marker in assisting CD diagnosis and deciding which patients to biopsy. (C) 1996, Editrice Kurtis.
引用
收藏
页码:267 / 272
页数:6
相关论文
共 50 条
  • [31] Costs of insulin-dependent diabetes mellitus
    Currie, C
    Peters, J
    DIABETIC MEDICINE, 1996, 13 (07) : 684 - 684
  • [32] Immunotherapy of insulin-dependent diabetes mellitus
    Bach, JF
    CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (05) : 601 - 605
  • [33] Insulin-dependent diabetes mellitus and glycosaminoglycans
    Hansen, C
    Irmscher, AK
    Kuhlemann, K
    Beyer, J
    Kahaly, G
    HORMONE AND METABOLIC RESEARCH, 1995, 27 (12) : 555 - 558
  • [34] Costs of insulin-dependent diabetes mellitus
    Simell, TT
    Sintonen, H
    Hahl, J
    Simell, OG
    PHARMACOECONOMICS, 1996, 9 (01) : 24 - 38
  • [35] Genetics of insulin-dependent diabetes mellitus
    Julier, C
    Hashimoto, L
    Lathrop, GM
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (03) : 354 - 360
  • [36] INSULIN-DEPENDENT DIABETES-MELLITUS
    BURCH, PRJ
    LANCET, 1984, 1 (8383): : 967 - 967
  • [37] Superantigens in insulin-dependent diabetes mellitus
    Luppi, P
    Trucco, M
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1996, 17 (04): : 333 - 362
  • [38] INSULIN-DEPENDENT DIABETES-MELLITUS
    BACH, JF
    CURRENT OPINION IN IMMUNOLOGY, 1991, 3 (06) : 902 - 905
  • [39] A Roofer with insulin-dependent Diabetes mellitus
    Pollmann, Hartmut
    Guenther, Ruth
    REHABILITATION, 2018, 57 (02) : 82 - 84
  • [40] Immunotherapy of insulin-dependent diabetes mellitus
    Masteller, EL
    Bluestone, JA
    CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (05) : 652 - 659